BMY·Bristol-Myers Squibb Company

The FDA has accepted BMY's NDA for iberdomide in combination with standard therapies for relapsed or refractory multiple myeloma, triggering a priority review. This is a significant development, with a decision expected by August 17, 2026. This acceptance, supported by positive clinical trial data from the EXCALIBER-RRMM study, could lead to a new treatment option and potentially boost BMY's revenue. The Breakthrough Therapy designation further supports the potential of iberdomide. BMY is also collaborating with Evinova, Astellas, and AstraZeneca to advance clinical development using Evinova's AI-native platform, aiming to accelerate clinical trials and improve patient outcomes. BioArctic AB, a BMY partner, reported record financial results in 2025, driven by the success of Lekembi and strategic partnerships. BMY offers a high dividend yield, but investors should consider the payout ratio and debt levels.